Capillary nano-immunoassay for Akt 1/2/3 and 4EBP1 phosphorylation in acute myeloid leukemia by Himalee Sabnis et al.
Sabnis et al. Journal of Translational Medicine 2014, 12:166
http://www.translational-medicine.com/content/12/1/166METHODOLOGY Open AccessCapillary nano-immunoassay for Akt 1/2/3 and
4EBP1 phosphorylation in acute myeloid leukemia
Himalee Sabnis1,2, Heath L Bradley1, Silvia T Bunting1,2, Todd M Cooper1,2 and Kevin D Bunting1*Abstract
Background: Overall cure rates in acute myeloid leukemia (AML) continue to range between 60-65% with disease
relapse being a major cause of mortality. The PI3K-Akt-mTOR kinase pathway plays a vital role in pro-survival signals
within leukemic cells and inhibition of this pathway is being investigated to improve patient outcomes. Tracking
activation of multiple signaling proteins simultaneously in patient samples can be challenging especially with
limiting cell numbers within rare sub-populations.
Methods: The NanoPro 1000 system (ProteinSimple) is built on an automated, capillary-based immunoassay
platform and enables a rapid and quantitative analysis of specific proteins and their phosphorylation states. We
have utilized this nano-immunoassay to examine activation of Akt 1/2/3 and downstream mTOR target - eukaryotic
initiation factor 4E-Binding Protein 1 (4EBP1).
Results: Assays for Akt 1/2/3 and 4EBP1 were standardized using AML cell lines (MV4-11, MOLM-14, OCI-AML3
and HL-60) prior to testing in patient samples. Target inhibition was studied using mTOR 1/2 inhibitor AZD-8055
and results were corroborated by Western blotting. The assay was able to quantify nanogram amounts of 4EBP1
and Akt 1/2/3 in AML cell lines and primary pediatric AML samples and results were quantifiable, consistent and
reproducible.
Conclusion: Our data provides a strong basis for testing this platform on a larger scale and our long term aim is
to utilize this nano-immunoassay prospectively in de-novo AML to be able to identify poor responders who might
benefit from early introduction of targeted therapy.
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Acute myeloid leukemia (AML) affects 16,000 -18,000
people annually in the United States and approximately
75% will succumb to the illness [1]. 6% of all patients
affected are under the age of 20 years [1]. In spite of
the advances made in the treatment of acute myeloid
leukemia with chemotherapy as well as hematopoietic
stem cell transplantation, overall cure rates remain at
60-65% with relapse being a major cause of mortality
[2]. Of those relapsed patients, only a third are salvage-
able with current treatment regimens [3,4]. Discovery of
both cytogenetic and molecular abnormalities in AML
has resulted in the development of the current prognos-
tic sub-groups in AML [5] and the molecular* Correspondence: kevin.bunting@emory.edu
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unless otherwise stated.abnormalities play an important role in leukemogenesis,
especially in patients with normal cytogenetics [6].
Downstream of these molecular aberrations in leukemic
cells, highly complex and inter-linked networks of signal-
ing pathways control cell survival growth, proliferation,
self renewal and differentiation. Up-regulation of the
PI3K-Akt-mTOR (PI3K-Akt-mammalian target of rapa-
mycin) pathway occurs via mutations in surface receptors
like FLT3, c-Kit or by mutations in the genes encoding
pathway constituents like PI3K, PTEN or Akt [7,8] . Akt is
a serine/threonine protein kinase that exists in three con-
served isoforms: Akt 1, 2 and 3. Of the three iso-forms
present, Akt 1 and 2 are expressed to a higher extent in
hematopoietic stem cells [9]. Akt is phosphorylated at Thr
308 by up-stream phosphoinositide-dependent protein
kinase 1 (PDK-1) and at Ser 473 by mTOR complex 2
(mTORC2). Akt plays an important role in key cellularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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cell cycle, and apoptosis through its multiple downstream
targets however activating mutations in Akt have not been
described in AML [10] . Akt can be constitutively phos-
phorylated in AML which results in depletion of normal
hematopoietic stem cells [11].
Activation of the mTOR pathway is seen in up to 80%
of AML patients and is associated with a shortened
overall survival. mTOR kinase is also a serine/threonine
kinase that complexes with other proteins [12]. mTORC2
mainly functions to phosphorylate and activate Akt
whereas mTORC1 plays a central role in the translational
machinery of normal and leukemic cells via its down-
stream targets - p70S6 Kinase and eukaryotic initiation
factor (eIF) 4E binding protein-1 (4EBP1) [12,13]. p70S6
Kinase phosphorylates the 40S ribosomal subunit protein
S6 and thereby allows translation of proteins involved in
cell growth and hypertrophy. 4EBP1 phosphorylation
results in release of the inhibition of eIF4E and enables
the formation of eIF4F complex. This complex is neces-
sary for the cap-dependent translation of highly structured
mRNAs which encode genes such as c-Myc, Mcl-1 and
VEGF that are involved in cell survival [13]. In certain
subtypes of AML (FAB M4/M5) eIF4E itself has been
shown to function as an oncogene via transcriptional up-
regulation by nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) [14]. Both p70S6 Kinase and
4EBP1 are downstream targets of mTOR however, inhib-
ition of 4EBP1 phosphorylation is key for ensuring efficacy
of mTOR antagonists [15]. Thus inhibiting downstream
mTOR targets has played a prominent role in anti-
leukemic therapy for several years and continues to be an
active area of research [12].
Molecular differences in Akt-mTOR pathway with
AML patients may provide key information to better
define the pathogenesis of disease, especially in patients
with normal cytogenetics. Traditionally, techniques such
as Western Blot and intra-cellular flow cytometry have
been used for this purpose but these have several limita-
tions - they require large number of cells, require tech-
nical expertise and quantitative results are difficult to
obtain. The NanoPro 1000 system (ProteinSimple) en-
ables a rapid and quantitative analysis of specific pro-
teins from small quantities of sample (dependent on cell
size and percentage of protein). The NanoPro provides
precise and quantitative data of the multi-site phosphor-
ylation states of a specific protein of interest. This degree
of phospho-protein specificity and rapid turn-around
time are unique. The system is built on an automated,
capillary based immunoassay platform. Proteins are sep-
arated by isoelectric focusing separation (PI) to resolve
the various modification states of proteins, immobilized,
and probed with specific antibodies. Signal intensity is
detected by a horseradish peroxidase-conjugated chemiluminescence system and the data is shown as an elec-
tropherogram. It can examine numerous proteins within
few cells using the same antibodies used in traditional
Western blots. This feature of the NanoPro 1000 makes it
a unique tool to look at signaling within rare leukemic cell
populations as it requires very small amounts (as low as
80 ng) of protein per capillary. It is also capable of simul-
taneously detecting multi-phosphorylation states of the
same protein which is impossible to do by Western Blot
or intracellular flow cytometry. We used the NanoPro
1000 platform on AML cell lines to standardize the assays
for 4EBP1 and Akt 1/2/3.
Methods
Cell lines
MV4-11, MOLM-14, OCI-AML3 and HL-60 cell lines
were used for this analysis. Cell lines were grown in
RPMI (MOLM-14), alpha-MEM (OCI-AML3) or IMDM
(MV4-11 and HL-60) and supplemented with 10% or
20% fetal bovine serum with 1% penicillin-streptomycin.
Cell density was maintained at 0.1 million cells/ml and
cultures were split every 48 hours maintaining cell via-
bility. Cells were harvested when confluent at 48 hours
for analysis of baseline signal using the NanoPro 1000
assay as outlined below. Cell lines were treated for
24 hours in the presence of specific inhibitors prior to
analysis.
Primary patient samples
Primary AML bone marrow samples were obtained
from the Children’s Oncology Group (COG) Myeloid
Diseases Reference Laboratory on pilot study protocol
AAML12B13. The study was approved by Emory Institu-
tional Review Board and the COG Myeloid Diseases
Committee. These bone marrow samples were obtained
from pediatric AML patients after written informed
consent at the time of diagnosis and were de-identified
prior to storage. Samples were ficolled to isolate mono-
nuclear cells and frozen with 10% DMSO. Information
provided to the investigators included age, gender, sam-
ple mono-nuclear cell count and FLT3 mutation status.
Samples were thawed at 37°C and placed in RPMI media
supplemented with 20% fetal bovine serum and 100 ng/
ml cytokines (IL-3, G-CSF, GM-CSF, SCF – Gemini Bio
Products Cat. #300-151P, #300-123P, #300-124P and
#300-185P respectively) for 24 hour drug effects. For
baseline analysis, samples were analyzed immediately
after thawing.
Drug treatment
AZD-8055 was obtained from Chemietek Biochemicals
(Cat. No. CT-A8055). It was dissolved in DMSO and
stored at −20 C. Both cell lines and primary AML sam-
ples were treated with AZD-8055 with concentrations
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strate target inhibition.
Western blotting
MV4-11 cells (5×106 cells) were treated for 1 hour with
AZD-8055 at concentrations ranging from 25–1000 nM
and with vehicle DMSO. Cell pellets were lysed in
150 μl Bicine Chaps lysis buffer (containing protease and
phosphatase inhibitor cocktail made as per Protein Sim-
ple specifications). Protein concentrations were deter-
mined by Bio-Rad protein assay. Proteins were separated
using SDS-polyacrylamide gels, transferred to polyviny-
lidene diflouride membranes (EMD Millipore) and
blocked in 5% non-fat dry milk. Primary antibody incu-
bations were performed overnight at 4°C, followed by
incubation in secondary horseradish peroxidase-linked
anti-rabbit or anti-mouse secondary antibody at room
temperature for 1 hour. Primary antibodies used were
total 4EBP1 (Cell Signal Cat #9644 s), phospho-serine
65 4EBP1(Cell Signal Cat #9451 s), phospho-threonine
37/46 4EBP1 (Cell Signal Cat #2855), total Akt 1/2/3
(Santa Cruz Cat #sc-8312), β-2 microglobulin (Abcam
Cat #ab75853) and β-actin (Sigma Cat #A5441). These
were used at a concentration of 1:1000 except for β-actin
(conc. 1:10,000) and secondary antibodies (Anti-mouse Cell
Signal Cat #7076S, Anti-rabbit Cell Signal Cat #7074S)
were used at a concentration of 1:2000.
Nano-immunoassay
All isoelectric separations were performed on the Nano-
Pro 1000 (ProteinSimple, Santa Clara, CA) by mixing 1
part lysate with 3 parts of ProteinSimple’s Generation 2
pH 5–8 (nested) separation gradient which contains a
pH 2–4 plug (Cat #040–972). Standard pI Ladder 3
(ProteinSimple Cat #040–646) supplemented with indi-
vidual pI Standard 5.5 (ProteinSimple Cat #040–028)
diluted 60 fold was added to the ampholyte pre-mix.
Lysates were then separated for 40 min at 21,000 μW in
individual capillaries. After separation the proteins in the
lysate were immobilized to the capillary wall by subject-
ing them to UV exposure for a period of 80 seconds.
After two washes of 150 seconds each, primary anti-
bodies were introduced into the capillaries for a period
of 2 hours. Antibodies for 4EBP-1 were used at a 1:25
dilution, whereas antibodies for AKT 1/2/3 and β-2
Microglobulin were used at 1:100 dilutions. After an-
other two washes of 150 seconds each, samples were run
either with or without amplification reagents. Secondary
anti-rabbit-HRP-conjugated antibodies (ProteinSimple
Cat #040–656) or secondary anti-rabbit-biotin-conju-
gated antibodies (ProteinSimple’s amplified rabbit sec-
ondary antibody kit - Cat #041–126) were loaded into
the capillary for 1 hour. Amplification was performed
only for 4EBP1 antibodies using primary patient samplesand AML cell lines. After a third set of two washes of
150 seconds each, either streptavidin, conjugated with
horse radish peroxidase (ProteinSimple Cat #041–126),
or antibody diluent was loaded into the capillary for
2 hours or 10 minutes respectively. After a final two
wash cycle of 150 seconds each, a luminol-peroxidase
1:1 mix (ProteinSimple Cat #040–0652 and 040–684)
was flowed through the capillaries and chemilumines-
cence was detected at 30, 60, 120, 240, 480, and 960 sec-
onds. Primary 4EBP1 antibodies used were similar to
those used for Western blotting and in addition rabbit
polyclonal total Akt1/2/3 (Santa Cruz Cat #sc-8312) was
used for the assay. To determine phospho-peaks, sample
lysates were pre-treated with 100 U lambda phosphatase
or vehicle according to the manufacturer’s instruc-
tions (Millipore, Cat #14-405). Lysates were incubated in
1× DTT-containing lambda phosphatase buffer for 1 hour
at 37°C before running on the NanoPro.
Statistical analysis
All data was derived as a result of three independent
experiments, unless stated otherwise. Two tailed t-test
was used to calculate p-values and values less than 0.05
were considered to be significant.
Results
The NanoPro 1000 platform can be used to measure
4EBP1 phosphorylation within AML cell lines and to
demonstrate target inhibition
We used AML cell lines to standardize assays for the
NanoPro 1000. AML cell lines were analyzed at baseline
for determination of total and phosphorylated forms of
4EBP1 (Figures 1 and 2). The pattern of 4EBP1 activa-
tion varied across cell lines. The total antibody was
capable of detecting both phosphorylated and non-
phosphorylated forms of the protein as depicted by the
electropherogram tracing using the total 4EBP1 antibody
(Figure 1-A). All samples were also treated with lambda
phosphatase and analyzed simultaneously to show sup-
pression of phosphorylation and an increase in the
amount of un-phosphorylated protein. β-2 microglobulin
was used as a loading control. We used the area-under-
curve (AUC) for the total 4EBP1 antibody to calculate
the percentage of phosphorylated forms of 4EBP1 in the
AML cell lines (Figure 1-B). Each line demonstrated
different degrees of phosphorylation – MV4-11 (36.9%),
MOLM-14 (34.7%), OCI-AML3 (29%) and HL60 (36.6%).
Treatment with lambda phosphatase resulted in a de-
creased percentage of phosphorylated forms of the protein
to 10.6% in MV4-11, 11.1% in MOLM-14, 8.1% in OCI-
AML3 and 6.7% in HL60 cells and these differences were
statistically significant (p-value <0.05). Interestingly, OCI-
AML3 cells showed a unique peak pattern from the other
3 cell lines with 2 additional peaks that were resistant to
Figure 1 Measurement of total 4EBP1 in AML cell lines. A) Electropherogram depicting levels of total and phosphorylated 4EBP1 in AML cell
lines. AML cell lines MV4-11, MOLM-14, OCI-AML3 and HL60 were analyzed at baseline for expression of 4EBP1. 80 ng of protein was used for
analysis. β-2 Microglobulin was used as loading control. Total 4EBP1 antibody detects both phosphorylated and non-phosphorylated protein. Samples
were treated with lambda-phosphatase or reaction buffer alone and decrease in phosphorylation was noted. X-axis represents iso-electric pH and
y-axis represents luminescence units. B) Change in phosphorylation was measured at exposure times varying between 30–960 secs after phosphatase
treatment in all cell lines. The experiments were performed in triplicate (*p < 0.05).
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unknown but may be related to isoform specific expres-
sion. This difference highlights the importance of validat-
ing phospho-peaks in every cell line or patient sample.
Although the treatments in Figure 1 were well con-
trolled for the lambda phosphatase buffer and incuba-
tion time, the treatment conditions alone modified
the pI of the peaks relative to un-manipulated samples
shown in Figure 2 (compare total 4EBP1 peaks). Sample
lysates not treated with lambda phosphatase or vehicle
had the same number of peaks but the isoelectric points
differed. This does not affect the ability of the assay to
accurately determine the percentage of phosphorylated
protein, however, to further test antibodies that are
specific to phosphorylated 4EBP1 we tested additional
antibodies. Serine 65 4EBP1 antibody is specific for the
phosphorylation site and showed a single peak profile
within each cell line that varied between 4.5 - 4.7 within
cell lines. The Threonine 37/46 antibody was able todetect site specific phosphorylation but also demon-
strated capability of detecting non-phosphorylated forms
as evident from the electropherogram tracing, although
the signal of the phosphorylated peaks was much higher.
The intensity of signal using phospho-specific antibodies
was much lower than the signal detected by the total
4EBP1 antibody (reasons not completely understood).
β-2 microglobulin was used as a loading control.
In order to validate the ability of this platform to detect
specific target inhibition, we treated MV4-11 cells with
specific mTOR 1/2 inhibitor AZD-8055 (25–1000 nM) for
1 hour. Cell lysates were obtained and analyzed simultan-
eously by Western blotting and by nano-immunoassay
(Figure 3). The nano-immunoassay was performed using
80 ng of protein and was able to demonstrate a dose
dependent decrease in phosphorylation with increasing
concentrations of the drug as expected using total and
phospho-specific 4EBP1 antibodies (Figure 3-A). Treat-
ment with AZD-8055 resulted in a shift of the peak profile
Figure 2 Measurement of phosphorylated 4EBP1 within AML cell lines. AML cell lines MV4-11, MOLM-14, OCI-AML3 and HL60 were analyzed
at baseline using total 4EBP1, phospho-specific Serine 65 and Threonine 37/46 4EBP1 antibodies. β-2 Microglobulin was used as loading control.
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phosphorylated protein were reduced and there was a
compensatory increase in the non-phosphorylated more
basic peaks. The phospho-specific Ser 65 and Thr 37/46
antibodies showed a dose dependent decrease in the phos-
phorylation with a decrease in the acidic peak profile. β-2
microglobulin was used as a loading control for the nano-
immunoassay and showed even loading across all samples
(Figure 3-B). Western blotting performed using 10 μg of
protein demonstrated a similar pattern with decreased
phosphorylation with increasing concentration of AZD-
8055 (Figure 3-C).
Total Akt 1/2/3 antibody can be used to measure total
and phosphorylated forms using nano-immunoassay in
AML cell lines
Similar to 4EBP1 protein, we standardized the nano-
immunoassay in AML cell lines for Akt 1/2/3 antibody.
The total Akt 1/2/3 antibody was used which was capable
of detecting both phosphorylated and non-phosphorylated
forms. Specific phospho-Akt antibody assay is currently
not standardized in our lab on the nano-immunoassay
platform. AML cell lines were analyzed at baseline for
expression of Akt 1/2/3 (Figure 4). Akt 1/2/3 expression
and activation varied with all cell lines (Figure 4-A). In
order to determine the specificity of the more acidic peaksfor the phosphorylated protein, each line was treated with
lambda-phosphatase concurrently and the electrophe-
rogram pattern revealed complete suppression of the
phosphorylated peaks as expected and increase in the
non-phosphorylated protein peaks. Our data showed ex-
pression of Akt 1 and 2 as expected in hematopoietic cells
and was consistent with recently reported identification of
the isoforms of the protein [16]. The non-phosphorylated
forms of Akt 1 are detected in the pI range 5.6 – 5.8 and
the non-phosphorylated form of Akt 2 is present in the
5.9 – 6.0 pI range. From the electropherogram it appears
as though Akt 2 rather than Akt 1 is the predominant
isoform in HL60 cell line and Akt 1 is present in higher
quantities in MV4-11, MOLM-14 and OCI-AML3 cell
lines. β-2 microglobulin was used as a loading control and
demonstrated equal loading in both phosphatase-treated
and non-treated samples. Results were further analyzed
by AUC to determine the degree of phosphorylation
within each cell line (Figure 4-B). Akt 1/2 was found to be
phosphorylated similarly in MV4-11 (81.5%), MOLM-14
(85.2%) and OCI-AML3 (79.2%) cell lines and phosphory-
lated to a lower degree in HL60 (59.6%) cell line. Although
the cell lines differed in the degree of Akt 1/2 activation
/phosphorylation, treatment with phosphatase showed a
significant decrease in the AUC for the phosphorylated
peaks on phosphatase treatment to 2.3% in MV4-11, 1.8%
Figure 3 Use of 4EBP1 assay to examine target inhibition within MV4-11 cell line. MV4-11 cells were treated with mTOR1/2 inhibitor
AZD-8055 (25 – 1000 nM) for one hour and inhibition of 4EBP1 phosphorylation was noted using the NanoPro 1000 and Western blotting.
A) Electropherogram shows the decrease in signal using both total and phospho-specific antibodies. B) β-2 Microglobulin was used as loading
control. X-axis represents iso-electric pH and y-axis represents luminescence units. C) Western blotting confirms the same results with GAPDH as
loading control.
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lines with the differences being statistically significant
(p < 0.05).
In order to demonstrate linearity of the signal intensity
for total and phosphorylated 4EBP1 and total Akt, we
plotted signal intensity against exposure time ranging
from 30–960 secs for each antibody. The assay was run
in triplicate for each cell line and results are shown in
Figure 5. 4EBP1 antibodies are depicted in Figure 5-A
and total Akt 1/2/3 antibody is depicted in Figure 5-B &
C. The linearity of the signal was dependent on the
duration of exposure and the abundance of the protein
within the sample as demonstrated by the pattern for
each antibody. At higher exposure times (240–960 secs),
the signal for all antibodies exhibited a logarithmic in-
crease in intensity and burn-out at high intensity. From
data obtained in the baseline runs, it was evident that
less than 40% of 4EBP1 is phosphorylated within these
cell lines. In samples where the protein of interest was
low (eg. Phospho-4EBP1), lower exposure times (30–120
secs) resulted in a linear increase (R-square value >0.94)
in signal intensity, as was evident for both Serine 65 and
Threonine 37/46 antibodies using 80 ng of protein per
capillary. For proteins that are present in higher
amounts such as total Akt 1/2/3, lower exposure times(between 30–120 secs) exhibited a less linear increase
in signal intensity (R-square values between 0.8-0.99)
and more abundant proteins such as 4EBP1 exhibited
even less linear increases with R-square values between
0.2-0.9. To test the assumption that amount of protein
was important for signal linearity, we repeated the total
4EBP1 assay by further titrating protein loading to 40
and 20 ng of protein and demonstrated sequential
improvement in the linearity of the signal at lower con-
centrations of protein (See Additional file 1: Figure S1).
Thus we believe that the adjustment of protein quantity
per capillary is an important factor to be considered
when setting up these assays.
Nano-immunoassay provides a reliable and sensitive
measurement of 4EBP1 and Akt activation in primary
patient samples
Primary pediatric bone marrow samples were obtained
from patients enrolled on the Children’s Oncology Group
trial AAML 0531. Samples were examined for baseline
activation of 4EBP1 (Figure 6). A total of 1.6 × 106 cells
were lysed in 18 μl of lysis buffer and used for this baseline
analysis which accounted for approximately 8888 cells per
capillary. The signals obtained using the phosphorylated
antibodies was extremely low so the signal from the
Figure 4 Measurement of total and phosphorylated Akt 1/2/3 in AML cell lines. A) Electropherogram depicting levels of total Akt 1/2/3 in
AML cell lines. AML cell lines MV4-11, MOLM-14, OCI-AML3 and HL60 were analyzed at baseline for activation of Akt. 80 ng of protein was used
for analysis. β-2 Microglobulin was used as loading control. Total Akt antibody detects both phosphorylated and non-phosphorylated protein
which is demonstrated on treatment with phosphatase. X-axis represents iso-electric pH and y-axis represents luminescence units. B) Different
AML cell lines exhibit different levels of Akt phosphorylation as demonstrated using total Akt 1/2/3 antibody and the phosphorylation is diminished on
treatment with lambda phosphatase. The experiments were performed in triplicate (*p < 0.05).
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primary samples were treated with AZD-8055 (500 nM)
for 24 hours and the changes in the peak profile were
used to determine the phosphorylated peaks within
samples (n = 8). Two representative samples are shown
in Figure 6-A. Treatment with AZD-8055 resulted in a
decrease in phosphorylated peaks and an increase in the
un-phosphorylated more basic peaks. β-2 microglobulin
was used as a loading control. A total of 11 samples
were probed with the total 4EBP1 antibody and all anti-
body signals were amplified using streptavidin-biotin
amplification reagent. We further used the AUC to
calculate the percentage of phosphorylated 4EBP1 in
each AML sample. The range of 4EBP1 phosphorylation
varied widely from 25.5 – 61.5% (Figure 6-B). Since
4EBP1 is a ubiquitous and abundant protein, it is likely
that phosphorylation is only transient within cells andmight account for the wide range of activation seen in
the primary samples.
Each sample was also analyzed for activation of Akt
1/2/3 using total Akt 1/2/3 antibody (Figure 7). In order
to determine phosphorylated peaks, samples were
treated with lambda phosphatase (n = 4) which showed a
decrease in the acidic peaks with corresponding increase
in the basic peaks as expected with inhibition of phos-
phorylation. Two representative samples are shown in
Figure 7-A. β-2 microglobulin was used as a loading
control. We used the AUC to further calculate the per-
centage of phosphorylated protein within each sample.
As opposed to 4EBP1, Akt 1/2/3 showed higher degrees
of phosphorylation ranging from 67.2 – 97.3% (n = 11).
This may be likely due to the fact that 4EBP1 phosphor-
ylation is transient whereas Akt is constitutively phos-
phorylated at certain sites [17].
Figure 5 Exposure time and protein amount is important for accurate measurement of signal. The intensity of signal (AUC) for total and
phosphorylated 4EBP1 (A) and total Akt 1/2/3 (B & C) was examined at exposure times between 30–960 seconds in MV4-11, MOLM-14, OCI-AML3 and
HL60 cells. Higher exposure times (240–960 secs) resulted in signal burn-out which was not observed at lower exposure times (30–120 secs). More
abundant proteins such as 4EBP1 exhibit improved linearity in signal with titration of protein loading (Additional file 1: Figure S1).
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primary cells, we performed sequential dilution of the
primary bone marrow samples (n = 3) and analyzed the
signal with total and phosphorylated 4EBP1 antibodies
and total Akt 1/2/3 antibody (Figure 8). A total of 16 ×
106 cells were lysed in 140 μl lysis buffer and protein con-
centrations were determined. Samples were run in dupli-
cate on the assay plate at cell numbers ranging from
10,000 to 313 cells per capillary which corresponded to
protein concentrations ranging from 370 ng to 5.9 ng of
protein per capillary. It is important to note that protein
concentrations can vary from sample to sample in spite of
having similar cell numbers since it is dependent on fac-
tors such as percentage of blasts in bone marrow, size of
blasts etc. The AUC for each antibody was plotted against
cell numbers per capillary for each of the samples. A dose-
dependent increase in signal was noted with increasing
cell numbers (Figure 8A-D) with R-squared values >0.92
except for sample A52453 –Thr 37/46 4EBP1 with R-
squared value of 0.88. Thus the assay was fairly robust
over a wide range of protein concentrations (5.9 - 370 ng)
and cell numbers (313–10,000) per capillary.Discussion
Acute myeloid leukemia continues to be a therapeutic
challenge with low overall survival rates and high inci-
dence of relapse. Development of improved biological
correlates that define the disease may allow for risk
stratification of patients that can be incorporated into
current risk strata based on cytogenetic and molecular
abnormalities. Defining the activation status of the
4EBP1 and Akt 1/2/3 proteins can serve as an important
indicator of signal transduction in AML and can poten-
tially provide information of prognostic significance.
Using the nano-immunoassay platform we were able to
standardize assays for both 4EBP1 and Akt 1/2/3 in
AML cell lines.
Traditionally, Western blotting and intra-cellular flow
cytometry have been used to study individual protein
activation. However both of these techniques need a
large number of cells, are unable to look at multiple sites
in the same protein in the same assay, and in the case of
flow cytometry require significant operator expertise.
The NanoPro assays have the advantage of being auto-
mated and are amenable to clinical translation due to
Figure 6 Measurement of total and phosphorylated 4EBP1 in primary AML samples. A) Samples (n = 8) were treated with 500 nM AZD-8055
and electropherogram demonstrated decrease in phosphorylated forms using total 4EBP1 antibody. Two representative samples are shown. β-2
Microglobulin was used as loading control. X-axis represents iso-electric pH and y-axis represents luminescence units. B) Primary AML patient samples
were examined at baseline for total and phosphorylated forms of 4EBP1 and expressed as percentage phosphorylated against sample number (n = 11).
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data acquisition. While not capable of providing the
depth of information on single cells that can be achieved
from flow cytometry analysis, the nano-immunoassay
platform can be combined with flow cytometry sortingto characterize rare AML sub-populations. Enrichment
of whole AML bone marrow or peripheral blood for
important cell subsets such as CD34+CD38− populations
can be achieved by flow cytometry and subsequently
these cells can be lysed and analyzed using the NanoPro
Figure 7 Measurement of total and phosphorylated Akt 1/2/3 in primary AML samples. A) Samples (n = 4) were treated with lambda
phosphatase and electropherogram demonstrated decrease in phosphorylated forms using total Akt 1/2/3 antibody. Two representative samples
are shown. β-2 Microglobulin was used as loading control. X-axis represents iso-electric pH and y-axis represents luminescence units. B) Primary
AML patient samples were examined at baseline for total and phosphorylated forms of Akt 1/2/3 and expressed as percentage phosphorylated
against sample number (n = 11).
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tage of being able to study different phospho-proteins in
gated populations but can also be limited by the numberof phospho-proteins studied simultaneously (typically
<12) and can be technically challenging. The NanoPro
technology supplements flow cytometry with the ability
Figure 8 The Nanopro 1000 is capable of detecting signal using low cell numbers in primary AML samples. Three independent primary
AML samples (A47316, A52453 and A52707) were used to test the capability of the assay to detect signal. Antibodies tested were Total 4EBP1
(A), Total Akt 1/2/3 (B), Phospho-4EBP1 Thr 37/46 (C) and Phospho-4EBP1 Ser 65 (D) Cell numbers ranged from 10,000-313 cells per capillary.
Signal intensity (AUC, log-scale, y-axis) was plotted against cell numbers (log-scale, x-axis) and showed a linear increase with increasing cell numbers.
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post-translational modifications such as acetylation and
methylation. Since the separation of the protein is based
on iso-electric pH, this platform can use total protein
antibodies to determine multi-phosphorylation events
as demonstrated here for 4EBP1 and Akt1/2/3 since
heavily phosphorylated proteins tend to have lower
iso-electric pH.
More recently, Reverse Phase Protein Array (RPPA)
analysis has been used to study the effects of protein
expression and modification in tumor samples [18].
RPPA is a high-throughput antibody based technique
capable of screening a large number of antibodies in a
single assay however our nano-immunoassay has certain
advantages. Detection of multiple phosphorylation states
of a protein using RPPA requires the use of multiple
phospho-specific antibodies while in case of the nano-
immunoassay, a single total antibody (eg. Akt 1/2/3) can
provide accurate information about multiple phosphor-
ylation sites. RPPA also has a much longer turn-around
time of several weeks whereas the NanoPro can provide
results within 24 hours making it a viable option for
real-time analysis of patient samples.Considering the above mentioned advantages of the
NanoPro system, we standardized the assays for 4EBP1
and Akt 1/2/3. Depending on the antibody and the
degree of expression, we were able to detect a signal for
most antibodies with as low as 80 ng of protein per ca-
pillary and in certain cases (total 4EBP1) even as low as
20 ng per capillary. The assays were robust with a short
turn-around time of 24 hours providing results that were
quantitative and easy to interpret. We further tested
these assays in primary bone marrow samples from
pediatric AML patients and found the results to be con-
sistent and reproducible. Primary cells are smaller than
cell lines but we were able to reliably detect signal in as
low as 40–96 ng of protein. Although the amount of
protein needed for performing these assays per capillary
is low, there are certain limiting factors that can affect
the sample preparation that need consideration. Firstly,
though cell counts for AML blasts might be high in
samples, these cells are still fairly small in size as com-
pared to AML cell lines. The recommended amount of
protein per capillary is 80 ng which corresponds roughly
to 2500 primary AML cells and ranged from 900–1400
cells from cultured AML cell lines. Secondly, in order to
Sabnis et al. Journal of Translational Medicine 2014, 12:166 Page 12 of 13
http://www.translational-medicine.com/content/12/1/166achieve these numbers, we had to lyse at least 1.6
million primary cells in lysis buffer to be able to obtain
adequate signal for each antibody. Therefore, future
studies that focus on leukemia stem cells or minimal
residual disease would require incorporation of methods
for concentrating protein as part of the sample prepar-
ation prior to running on the NanoPro.
Both 4EBP1 and Akt are proteins that are phosphory-
lated on multiple sites. Using the nano-immunoassay we
were able to distinguish these multiple phosphorylated
forms in cell lines and primary AML samples. We tested
both AML cell lines and primary AML samples with
AZD-8055 mTOR 1/2 inhibitor and found that the drug
was effective at inhibiting 4EBP1 phosphorylation thus
making this technology useful to determine specific
target inhibition. We are also currently working on de-
veloping assays that cover the entire PI3K-Akt-mTOR
pathway. Assays for PI3K activation or p70S6K activa-
tion have been problematic and require additional devel-
opment. Therefore, it is possible that our assay could
miss some p70S6K activation through the ERK signaling
pathway. We could therefore combine the analysis of
Akt 1/2/3 and 4EBP1 phosphorylation with analysis
of pERK in future studies. The assay for pERK is well
described by several groups in non-hematologic cancers
[19] but thus far has not worked on AML samples in
our laboratory.
Since this was a pilot study utilizing a small number of
samples to highlight an emerging new technology, we
were unable to make any relevant prognostic conclusions
correlating signal strength to overall survival/relapse rates.
Our future studies will involve studying larger numbers of
patient samples with correlative outcome data as well as
comparison of samples at diagnosis and relapse to deter-
mine changes in protein activation. The utility of our
overall approach to study signal activation is broad and
could apply not only to leukemia but also to other cancers
where tumor samples might be limiting in number.Additional file
Additional file 1: Figure S1 Protein amount is important for
accurate measurement of signal. The amount of protein per capillary
was titrated (20–80 ng) in MV4-11, MOLM-14, OCI-AML3 and HL60 cell
lines and increase in signal linearity was observed with improvement of
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